Table 2.
Distribution of adjuvant chemotherapy regimens among patients
| Total (n=462) | <75 years (n=349) | ≥75 years (n=113) | P value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | ||||||||
| Single-agent chemotherapy | 298 | ( | 64.5 | %) | 207 | ( | 59.3 | %) | 91 | ( | 80.5 | %) | <0.001 |
| 5-FU/LV | 13 | ( | 2.8 | %) | 11 | ( | 3.2 | %) | 2 | ( | 1.8 | %) | |
| CAPE | 100 | ( | 21.6 | %) | 75 | ( | 21.5 | %) | 25 | ( | 22.1 | %) | |
| UFT/LV | 139 | ( | 30.1 | %) | 92 | ( | 26.4 | %) | 47 | ( | 41.6 | %) | |
| S-1 | 46 | ( | 10.0 | %) | 29 | ( | 8.3 | %) | 17 | ( | 15.0 | %) | |
| Double-agent chemotherapy | 164 | ( | 35.5 | %) | 142 | ( | 40.7 | %) | 22 | ( | 19.5 | %) | |
| FOLFOX | 35 | ( | 7.6 | %) | 26 | ( | 7.4 | %) | 9 | ( | 8.0 | %) | |
| CAPEOX | 126 | ( | 27.3 | %) | 114 | ( | 32.7 | %) | 12 | ( | 10.6 | %) | |
| SOX | 3 | ( | 0.6 | %) | 2 | ( | 0.6 | %) | 1 | ( | 0.9 | %) | |
5-FU/LV, fluorouracil plus leucovorin; CAPE, capecitabine; UFT/LV, uracil-tegafur plus leucovorin; S-1, tegafur/gimeracil/oteracil/potassium; FOLFOX, 5-FU/LV plus oxaliplatin; CAPEOX, CAPE plus oxaliplatin; SOX, S-1 plus oxaliplatin